REG - Genflow Biosciences - International patent application

Genflow BiosciencesAnnouncement

25/05/2022 08:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220525:nRSY6882Ma&default-theme=true

RNS Number : 6882M  Genflow Biosciences PLC  25 May 2022

 

PRESS RELEASE

25 May 2022

Genflow Biosciences Plc

("Genflow" or "the Company")

 

Patent portfolio strengthened with international patent application under the
Patent Cooperation Treaty

Genflow (LSE: GENF), is pleased to announce that it has filed an international
patent application in the US under the Patent Cooperation Treaty ("PCT")
related to variants of Sirtuin-6 ("SIRT6"), and the gene variant's therapeutic
uses in the regulation of aging and for the treatment and prevention of
age-related diseases (the "Application").

The patent has been filed jointly with the University of Rochester, a
prestigious private research university in New York, and Genflow holds the
exclusive licence through Genflow Biosciences SRL (the Company's Belgian
subsidiary). The Application claims priority from the provisional application
US 63/188,573 of May 14, 2021. Full details of the exclusive licence are set
out in the Company's prospectus which can be found on its website.

The Company believes that the invention set out in the Application has the
potential to enhance both health-span and, possibly, life expectancy. The
SIRT6 gene variant found in centenarians (people aged more than 100 years old)
has demonstrated significant capabilities in epigenetic tissue rejuvenation
and therefore, constitutes an excellent target to prevent and treat
age-related diseases. The ability of SIRT6 to act on the rejuvenation of cells
is indicative of the SIRT6 gene mutation's potential to not just halt the
aging process, but to reverse it.

The filing will strengthen Genflow's intellectual property portfolio
establishing a patent footprint for the Company in the US and internationally.
By filing an 'international' patent application with the PCT Genflow is
allowed to seek patent protection for the relevant invention simultaneously in
a large number of countries. In addition, use of the PCT will reduce
administration for the Company and lead to lower costs and moreover, support
the Company's decisions concerning the prosecution of the application before
different national patent offices in the PCT National Phase of processing.

This Application is in addition to a previously filed patent application for
the method of administration and delivery of the Company's product into humans
and dogs, using Genflow's lead compound, GF-1002, a recombinant
self-complementary adeno-associated virus ("AAV").

Dr Eric Leire, Founder and CEO of Genflow, said: "I am proud of the excellent
progress that Genflow has made by filing the patent and we look forward to
contributing to the growing body of research on longevity, while also
enhancing our patent portfolio. This marks a significant step in strengthening
our IP position."

For further information please contact:

 

 Genflow Biosciences Plc
 Dr Eric Leire                       via Tancredi +44 203 434 2330

 Chief Executive
 Clear Capital Markets Ltd
 Corporate Broker                    +44 203 869 6086

 Jonathan Critchley                  +44 203 897 0981

 Keith Swann
 Tancredi Intelligent Communication

 Media Relations
 Salamander Davoudi                  +44 7957 549 906

 Helen Humphrey                      +44 7449 226 720

 Benedetta Negri da Oleggio          +44 7838 029 970

                                     genflowbio@tancredigroup.com

 

About Genflow

Genflow is a UK-based biotechnology company established in 2020. The Company
is developing gene therapies designed to target the aging process and to
reduce and delay the incidence of age-related diseases. This will be done
through novel therapeutics targeting aging in humans by using adeno-associated
virus ("AAV") vectors to deliver copies of the Sirtuin-6 ("SIRT6") gene
variant that is found in centenarians into cells.

Its mission is to increase understanding of the factors that control and
impact lifespan. Genflow researches, develops, and commercialises therapeutic
solutions to lengthen health span, the amount of time we live in good health,
creating biological interventions that enable longer and healthier lives.
Genflow is dedicated to the development and commercialisation of novel
therapeutics targeting aging in dogs and humans. By treating aging, Genflow
can contribute to a decrease in healthcare costs and lessen the emotional and
societal burden that comes with an aging population.

To learn more visit www.genflowbio.com (http://www.genflowbio.com)

 

-Ends-

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCBKQBKNBKBDPB